Vaccines

#Clinical trial #Covid-19 #Drug development #Immunology / Virology & Vaccines #Research #Vaccines

NIH begins study of allergic reactions to Covid-19 vaccines

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech Covid-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of… Read More

#Covid-19 #News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #mRNA #Vaccines

New study provides global analysis of Covid-19 vaccines

A new study by Novateur Ventures provides a comparative analysis of twelve Covid-19 vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020. The study highlights the early successes, as well as the hurdles and barriers yet to be overcome for ending the global… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna’s Covid-19 vaccine antibody persistence data published

Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through six months following the second dose… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Vaccines

Valneva reports positive Phase I/II data for Covid-19 vaccine

Valneva, a specialty vaccine company focused on the development and commercialisation of prophylactic vaccines for infectious diseases with significant unmet medical need, has announced positive data for Part A of the Phase I/II clinical trial of its inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001. Based on this data, the company plans… Read More

#Covid-19 #News

T cells
#Antibodies #Covid-19 #Immunology / Virology & Vaccines #Online focus #Vaccines

T Cells recognise recent SARS-CoV-2 variants

When variants of SARS-CoV-2 emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More

#Covid-19 #News

#Biotherapeutics #Drug development #Immunology / Virology & Vaccines #Vaccines

ENPICOM accelerates antibody and vaccine discovery

Viroclinics-DDL, a Contract Research Organisation (CRO) specialising in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have announced the approval of a joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines in vitro diagnostic and high-throughput sequencing… Read More

#News

#Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Vaccines

GSK to support manufacture of Novavax’ Covid-19 vaccine

Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ Covid-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide… Read More

#Covid-19 #News

#Biotechnology #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Pharma #Vaccines

The effect of Covid-19 solutions on the clinical trials process

Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases at ICON, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership. The world responded to the Covid-19 crisis at unprecedented speed — including vaccine development. During a pandemic, timing… Read More

#Business & Investment #Covid-19 #Exclusive Content #News

#Big pharma #Biopharmaceuticals #Biotechnology #Covid-19 #Vaccines

Supply chains key to successful COVID-19 vaccine roll-out 

Resilience in pharma and biotech supply chains is essential for the roll out of the Covid-19 vaccine, says Karl Lauri, ERP/MRP software manufacturer and distributor MRPeasy.com.  While the pandemic has highlighted the strength of the UK’s pharmaceutical and biotechnology sector, it has also shed light on the vulnerabilities of intricate, geographically extended and… Read More

#Covid-19 #News

#AI #Assay development optimisation & technology #Biologics / Biotechnology #Cancer research #Drug development #Drug discovery #Vaccines

Latest issue of DDW now available

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as… Read More

#Editor's Choice #News

#Covid-19 #Vaccines

Vaccine innovation in the age of COVID-19 & beyond

Traditional approaches for vaccine discovery and development are being reimagined and accelerated - leveraging technologies in novel ways to streamline workflows and forging collaborations. Dr. Sanjay Garg and Dr. Anis H Khimani, discuss key learnings and best practices during COVID-19 vaccine research and how we can take these forward to… Read More

#Covid-19 #Exclusive Content #News

#Biologics #Biotechnology #Vaccines

German biotech Leukocare opens in the US

Leukocare, a German biotechnology company specialising in formulation development for biologics, viral vectors and vaccines, has opened development labs in Milford, USA. Its headquarters will remain in Martinsried/Munich, Germany. Being present in the US market offers the opportunity to collaborate closely with customers and partners on tailor-made solutions in the… Read More

#News

#Clinical trials #Covid-19 #Vaccines

The ethics of human challenge trials

Rutgers Research Professor, Daniel Hausman, examines the ethical questions around human challenge trials for COVID-19 vaccines The first human challenge trial to test COVID-19 treatments and vaccines is set to begin in January in the United Kingdom. These trials, in which healthy volunteers are infected with the virus after being… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Clinical trials #Covid-19 #Vaccines

Pfizer and BioNTech conclude Phase III study of Covid-19 vaccine, showing 95% efficacy

Pfizer and BioNTech have announced that after conducting the final efficacy analysis in their ongoing Phase III study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (first… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Cobra Biologics #Covid-19 #Scancell Holdings #Vaccines

Cobra Biologics to manufacture plasmids for Phase I clinical trial COVID-19 vaccine

Cobra Biologics is to manufacture Scancell Holdings COVID-19 vaccine. The agreement covers Good Manufacturing Practice (GMP) production of plasmid DNA needed to generate the DNA vaccine, against SARS-CoV-2, for use in a Phase I clinical trial in 2021 (COVIDITY). The project is funded by an Innovate UK grant awarded to… Read More

#Covid-19 #News